Doubling down on its in-house startup academy, biotech VC stalwart Flagship Ventures has recruited a trio of big-name corporate sponsors to lend their expertise to its next class of seedlings, expanding its focus well beyond traditional drug development.
New York City's nascent biotech investment fund is ready to get rolling, recruiting some venture capital partners to join Eli Lilly, Celgene and GE Ventures with hopes of pouring $150 million into the local life sciences startup scene.
Biotech VC stalwart Flagship Ventures put together a $537 million new fund, its largest ever, with eyes on a new generation of life sciences upstarts.
Biotech Seres Health has raised a quick $10 million B round to support its work in microbiome R&D, appending a partnership with the Mayo Clinic as it advances an infectious disease treatment.
After two years of building up its knowledge of the human microbiome, tiny Seres Health has emerged from stealth mode today with $10.5 million in venture cash from Flagship Ventures and a business plan to develop new therapies dubbed "Ecobiotics."
The startup biotech Blend Therapeutics rang in 2012 with seed cash and will now close out the year with a fresh injection of $16 million in B-round bucks budgeted to take this startup--one of the latest from the prolific scientist Robert Langer--right to the threshold of clinical development.
The secretive startup has attracted $40 million from Flagship Ventures and other investors to put the bold plan into action, disclosing the financing and details about its research to the public for the first time this morning.
French in vitro diagnostics giant bioMérieux has taken a major stake in Massachusetts startup Quanterix. It led most of a $18.5 million Series C financing secured by the company, and both will partner to develop ultrasensitive and multilevel immunoassays.
The Bill & Melinda Gates Foundation has stepped up with another equity investment in a biotech company, this time making a major contribution to a $13 million Series A add for a startup aiming at a universal preventive as well as therapeutic approach to influenza. Omega Funds also joined the venture top-up, bringing the first venture round for Cambridge, MA-based Visterra to $26 million.
Gone are the days when venture capitalists could hatch a biotech and take it public without much regard for the needs of Big Pharma. Public investors seldom buy into new biotech companies, and drugmakers have increasingly become early partners with VC firms and their young ventures. In the process, pharma has gained significant clout in the biotech VC game.